111 related articles for article (PubMed ID: 38215770)
1. Efficacy and safety of a structured de-escalation from antipseudomonal β-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial.
López-Cortés LE; Delgado-Valverde M; Moreno-Mellado E; Goikoetxea Aguirre J; Guio Carrión L; Blanco Vidal MJ; López Soria LM; Pérez-Rodríguez MT; Martínez Lamas L; Arnaiz de Las Revillas F; Armiñanzas C; Ruiz de Alegría-Puig C; Jiménez Aguilar P; Del Carmen Martínez-Rubio M; Sáez-Bejar C; de Las Cuevas C; Martín-Aspas A; Galán F; Yuste JR; Leiva-León J; Bou G; Capón González P; Boix-Palop L; Xercavins-Valls M; Goenaga-Sánchez MÁ; Anza DV; Castón JJ; Rufián MR; Merino E; Rodríguez JC; Loeches B; Cuervo G; Guerra Laso JM; Plata A; Pérez Cortés S; López Mato P; Sierra Monzón JL; Rosso-Fernández C; Bravo-Ferrer JM; Retamar-Gentil P; Rodríguez-Baño J;
Lancet Infect Dis; 2024 Apr; 24(4):375-385. PubMed ID: 38215770
[TBL] [Abstract][Full Text] [Related]
2. Targeted simplification versus antipseudomonal broad-spectrum beta-lactams in patients with bloodstream infections due to
López-Cortés LE; Rosso-Fernández C; Núñez-Núñez M; Lavín-Alconero L; Bravo-Ferrer J; Barriga Á; Delgado M; Lupión C; Retamar P; Rodríguez-Baño J;
BMJ Open; 2017 Jun; 7(6):e015439. PubMed ID: 28601833
[TBL] [Abstract][Full Text] [Related]
3. In
Ouranos K; Mylonakis E
Ann Intern Med; 2024 May; 177(5):JC52. PubMed ID: 38710092
[TBL] [Abstract][Full Text] [Related]
4. Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial.
Dinh A; Ropers J; Duran C; Davido B; Deconinck L; Matt M; Senard O; Lagrange A; Makhloufi S; Mellon G; de Lastours V; Bouchand F; Mathieu E; Kahn JE; Rouveix E; Grenet J; Dumoulin J; Chinet T; Pépin M; Delcey V; Diamantis S; Benhamou D; Vitrat V; Dombret MC; Renaud B; Perronne C; Claessens YE; Labarère J; Bedos JP; Aegerter P; Crémieux AC;
Lancet; 2021 Mar; 397(10280):1195-1203. PubMed ID: 33773631
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of switching from intravenous to oral antibiotics (amoxicillin-clavulanic acid) versus a full course of intravenous antibiotics in neonates with probable bacterial infection (RAIN): a multicentre, randomised, open-label, non-inferiority trial.
Keij FM; Kornelisse RF; Hartwig NG; van der Sluijs-Bens J; van Beek RHT; van Driel A; van Rooij LGM; van Dalen-Vink I; Driessen GJA; Kenter S; von Lindern JS; Eijkemans M; Stam-Stigter GM; Qi H; van den Berg MM; Baartmans MGA; van der Meer-Kappelle LH; Meijssen CB; Norbruis OF; Heidema J; van Rossem MC; den Butter PCP; Allegaert K; Reiss IKM; Tramper-Stranders GA
Lancet Child Adolesc Health; 2022 Nov; 6(11):799-809. PubMed ID: 36088952
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of de-escalation therapy to ertapenem for treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae: an open-label randomized controlled trial.
Rattanaumpawan P; Werarak P; Jitmuang A; Kiratisin P; Thamlikitkul V
BMC Infect Dis; 2017 Mar; 17(1):183. PubMed ID: 28249572
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trial.
Kaasch AJ; López-Cortés LE; Rodríguez-Baño J; Cisneros JM; Dolores Navarro M; Fätkenheuer G; Jung N; Rieg S; Lepeule R; Coutte L; Bernard L; Lemaignen A; Kösters K; MacKenzie CR; Soriano A; Hagel S; Fantin B; Lafaurie M; Talarmin JP; Dinh A; Guimard T; Boutoille D; Welte T; Reuter S; Kluytmans J; Martin ML; Forestier E; Stocker H; Vitrat V; Tattevin P; Rommerskirchen A; Noret M; Adams A; Kern WV; Hellmich M; Seifert H;
Lancet Infect Dis; 2024 May; 24(5):523-534. PubMed ID: 38244557
[TBL] [Abstract][Full Text] [Related]
8. Switch to oral antibiotics in Gram-negative bacteraemia: a randomized, open-label, clinical trial.
Omrani AS; Abujarir SH; Ben Abid F; Shaar SH; Yilmaz M; Shaukat A; Alsamawi MS; Elgara MS; Alghazzawi MI; Shunnar KM; Zaqout A; Aldeeb YM; Alfouzan W; Almaslamani MA;
Clin Microbiol Infect; 2024 Apr; 30(4):492-498. PubMed ID: 37858867
[TBL] [Abstract][Full Text] [Related]
9. Pivmecillinam with Amoxicillin/Clavulanic acid as step down oral therapy in febrile Urinary Tract Infections caused by ESBL-producing Enterobacterales (PACUTI).
Tverring J; Månsson E; Andrews V; Ljungquist O
Trials; 2023 Sep; 24(1):568. PubMed ID: 37660037
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Bassetti M; Echols R; Matsunaga Y; Ariyasu M; Doi Y; Ferrer R; Lodise TP; Naas T; Niki Y; Paterson DL; Portsmouth S; Torre-Cisneros J; Toyoizumi K; Wunderink RG; Nagata TD
Lancet Infect Dis; 2021 Feb; 21(2):226-240. PubMed ID: 33058795
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial.
de Vries HJC; de Laat M; Jongen VW; Heijman T; Wind CM; Boyd A; de Korne-Elenbaas J; van Dam AP; Schim van der Loeff MF;
Lancet Infect Dis; 2022 May; 22(5):706-717. PubMed ID: 35065063
[TBL] [Abstract][Full Text] [Related]
12. Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial.
Kokai-Kun JF; Roberts T; Coughlin O; Le C; Whalen H; Stevenson R; Wacher VJ; Sliman J
Lancet Infect Dis; 2019 May; 19(5):487-496. PubMed ID: 30885591
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis (CHOICE): a single-centre, open-label, randomised, controlled, non-inferiority trial.
Ibrahim LF; Hopper SM; Orsini F; Daley AJ; Babl FE; Bryant PA
Lancet Infect Dis; 2019 May; 19(5):477-486. PubMed ID: 30853250
[TBL] [Abstract][Full Text] [Related]
14. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.
Zhanel GG; Pozdirca M; Golden AR; Lawrence CK; Zelenitsky S; Berry L; Schweizer F; Bay D; Adam H; Zhanel MA; Lagacé-Wiens P; Walkty A; Irfan N; Naber K; Lynch JP; Karlowsky JA
Drugs; 2022 Apr; 82(5):533-557. PubMed ID: 35294769
[TBL] [Abstract][Full Text] [Related]
15. Methenamine hippurate compared with antibiotic prophylaxis to prevent recurrent urinary tract infections in women: the ALTAR non-inferiority RCT.
Harding C; Chadwick T; Homer T; Lecouturier J; Mossop H; Carnell S; King W; Abouhajar A; Vale L; Watson G; Forbes R; Currer S; Pickard R; Eardley I; Pearce I; Thiruchelvam N; Guerrero K; Walton K; Hussain Z; Lazarowicz H; Ali A
Health Technol Assess; 2022 May; 26(23):1-172. PubMed ID: 35535708
[TBL] [Abstract][Full Text] [Related]
16. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial.
Kim HS; Kang J; Hwang D; Han JK; Yang HM; Kang HJ; Koo BK; Rhew JY; Chun KJ; Lim YH; Bong JM; Bae JW; Lee BK; Park KW;
Lancet; 2020 Oct; 396(10257):1079-1089. PubMed ID: 32882163
[TBL] [Abstract][Full Text] [Related]
17. The clinical and microbiological efficacy of temocillin versus cefotaxime in adults with febrile urinary tract infection, and its effects on the intestinal microbiota: a randomised multicentre clinical trial in Sweden.
Edlund C; Ternhag A; Skoog Ståhlgren G; Edquist P; Östholm Balkhed Å; Athlin S; Månsson E; Tempé M; Bergström J; Giske CG; Hanberger H;
Lancet Infect Dis; 2022 Mar; 22(3):390-400. PubMed ID: 34756180
[TBL] [Abstract][Full Text] [Related]
18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
19. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial.
Kim CJ; Park MW; Kim MC; Choo EH; Hwang BH; Lee KY; Choi YS; Kim HY; Yoo KD; Jeon DS; Shin ES; Jeong YH; Seung KB; Jeong MH; Yim HW; Ahn Y; Chang K;
Lancet; 2021 Oct; 398(10308):1305-1316. PubMed ID: 34627490
[TBL] [Abstract][Full Text] [Related]
20. Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales ("MERINO-3"): study protocol for a multicentre, open-label randomised non-inferiority trial.
Stewart AG; Harris PNA; Chatfield MD; Littleford R; Paterson DL
Trials; 2021 Apr; 22(1):301. PubMed ID: 33888139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
